What is the official website of Fresenius Kabi Polska ?

The official website of Fresenius Kabi Polska is https://www.fresenius-kabi.com/pl/.

What is Fresenius Kabi Polska's cybersecurity risk score?

Fresenius Kabi Polska has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Fresenius Kabi Polska experienced?

According to Rankiteo, Fresenius Kabi Polska currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Fresenius Kabi Polska been affected by any supply chain cyber incidents ?

According to Rankiteo, Fresenius Kabi Polska has been affected by a supply chain cyber incident involving Fresenius Kabi USA, with the incident ID FRE1781735374.

Does Fresenius Kabi Polska have SOC 2 Type 1 certification ?

According to Rankiteo, Fresenius Kabi Polska is not certified under SOC 2 Type 1.

Does Fresenius Kabi Polska have SOC 2 Type 2 certification ?

According to Rankiteo, Fresenius Kabi Polska does not hold a SOC 2 Type 2 certification.

Does Fresenius Kabi Polska comply with GDPR ?

According to Rankiteo, Fresenius Kabi Polska is not listed as GDPR compliant.

Does Fresenius Kabi Polska have PCI DSS certification ?

According to Rankiteo, Fresenius Kabi Polska does not currently maintain PCI DSS compliance.

Does Fresenius Kabi Polska comply with HIPAA ?

According to Rankiteo, Fresenius Kabi Polska is not compliant with HIPAA regulations.

Does Fresenius Kabi Polska have ISO 27001 certification ?

According to Rankiteo,Fresenius Kabi Polska is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Fresenius Kabi Polska operate in ?

Fresenius Kabi Polska operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Fresenius Kabi Polska have ?

Fresenius Kabi Polska employs approximately 126 people worldwide.

Does Fresenius Kabi Polska own any subsidiaries ?

Fresenius Kabi Polska presently has no subsidiaries across any sectors.

How many LinkedIn followers does Fresenius Kabi Polska have ?

Fresenius Kabi Polska's official LinkedIn profile has approximately 2,441 followers.

What is the NAICS classification code for Fresenius Kabi Polska ?

Fresenius Kabi Polska is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Fresenius Kabi Polska have a Crunchbase profile ?

No, Fresenius Kabi Polska does not have a profile on Crunchbase.

Does Fresenius Kabi Polska have a LinkedIn profile ?

Yes, Fresenius Kabi Polska maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/fresenius-kabi-polska.

How many cybersecurity incidents has Fresenius Kabi Polska experienced ?

As of July 26, 2026, Rankiteo reports that Fresenius Kabi Polska has experienced 3 cybersecurity incidents.

How many peer or competitor companies does Fresenius Kabi Polska have ?

Fresenius Kabi Polska has an estimated 5,709 peer or competitor companies worldwide.

What types of cybersecurity incidents has Fresenius Kabi Polska faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FKP

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Fresenius Kabi Polska Vendor Cyber Rating & Cyber Score

fresenius-kabi.com

Add Your Compliance Badge

Misją Fresenius Kabi jest #troska_o_życie. Zapewniamy dostęp do żywienia medycznego, płynów infuzyjnych, leków dożylnych, technologii infuzyjnej i transfuzyjnej. W portfolio posiadamy też leki biopodobne oraz ketoanalogi aminokwasów – wspierające terapię Przewlekłej Choroby Nerek w okresie poprzedzającym dializy. Za pośrednictwem spółki #DOM_Medica zapewniamy opiekę nad pacjentami domowymi w zakresie żywienia dojelitowego oraz wentylacji mechanicznej. Nasza #Wytwórnia_Płynów_Infuzyjnych w Kutnie jest największym w Polsce producentem płynów (w tym płynu wieloelektrolitowego o składzie zbliżonym do osocza: Optilyte), których znaczna część trafia do szpitali w całej Polsce, jak również glukozy, 0,9% NaCl, koloidów i antybiotyków.

FKP A.I CyberSecurity Scoring

Scoring History

FKP

Fresenius Kabi Polska CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Fresenius Kabi USA

Breach

100

1/2026

Fresenius Kabi ...

FRE1781735374

Fresenius Group

Ransomware

100

5/2020

FRE1770566194

Fresenius Kabi Pols...

Ransomware

05/2020

FRE2038291222

Loading…

A.I.

FKP Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FKP

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Polska in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Fresenius Kabi Polska in 2026.

Incident Types FKP vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Polska in 2026.

Incident History - FKP (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Fresenius Kabi Polska Subsidiaries

FKP

Pharmaceutical Manufacturing

Website: https://www.fresenius-kabi.com/pl/

Company Size: 126

Fresenius KabiPharmaceutical Manufacturing

Fresenius GroupHospitals and Health Care

Fresenius Digital TechnologyInformation Technology & Services

Fresenius Investor RelationsKrankenhäuser und Gesundheitseinrichtungen

Helios Health GmbHHospitals and Health Care

QuirónsaludWellness and Fitness Services

Helios Kliniken GmbHHospitals and Health Care

Fresenius Kabi BrasilPharmaceutical Manufacturing

Fresenius Kabi USAPharmaceutical Manufacturing

Fresenius Kabi FrancePharmaceutical Manufacturing

Fresenius Kabi UKPharmaceutical Manufacturing

MOTIV eLearningHospitals and Health Care

Fresenius Kabi ColombiaPharmaceutical Manufacturing

Fresenius Kabi EspañaPharmaceutical Manufacturing

Fresenius Kabi Asia PacificPharmaceutical Manufacturing

Fenwal, Inc., a Fresenius Kabi CompanyMedical Equipment Manufacturing

Fresenius Kabi EcuadorPharmaceutical Manufacturing

Fresenius Kabi CanadaPharmaceutical Manufacturing

Fresenius Kabi MedTech EuropeMedical Equipment Manufacturing

Fresenius Kabi EuropePharmaceutical Manufacturing

Fresenius Kabi ChilePharmaceutical Manufacturing

Fresenius Kabi ItaliaPharmaceutical Manufacturing

Fresenius Kabi AustriaPharmaceutical Manufacturing

Fresenius Kabi ArgentinaPharmaceutical Manufacturing

Fresenius Kabi Australia and New ZealandPharmaceutical Manufacturing

Fresenius Kabi Business ServicesAccounting

Fresenius Kabi DanmarkPharmaceutical Manufacturing

Fresenius Kabi South AfricaPharmaceutical Manufacturing

Fresenius Kabi IrelandPharmaceutical Manufacturing

Fresenius Kabi Viet Nam Pharmaceutical Manufacturing

Fresenius Kabi NetherlandsPharmaceutical Manufacturing

Fresenius Kabi SchweizPharmaceutical Manufacturing

Fresenius Kabi BelgiumPharmaceutical Manufacturing

Fresenius Kabi (Singapore) Pte Ltd, SingaporePharmaceutical Manufacturing

Fresenius Kabi Puerto RicoManufacturing

Unidos por la Nutrición Clínica MéxicoHospitals and Health Care

Fresenius Kabi MéxicoPharmaceutical Manufacturing

Loading…

Fresenius Kabi Polska Similar Companies

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Loading…

NEWS

Fresenius Kabi Polska CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-10681

SUMMARY

In Zephyr's userspace dynamic-objects subsystem, thread_idx_alloc() in kernel/userspace/userspace.c allocated a new thread permission index from the global _thread_idx_map[] bitmap without holding lists_lock. On SMP systems, two user-mode threads invoking the k_object_alloc(K_OBJ_THREAD) syscall concurrently can both observe the same low free bit, perform the same non-atomic RMW to clear it, and return the identical tidx. The two newly created K_OBJ_THREAD objects are then assigned the same thread_id, so the two user threads alias a single bit position in every kernel object's perms[] bitfield: any subsequent grant of access on a kernel object to one thread is implicitly a grant to the other, defeating userspace ACL isolation. A secondary lost-update window between the unlocked &=~BIT() in alloc and the locked |= BIT() in thread_idx_free() can also leak entries from the thread-index pool. The defect is reachable from any user-mode thread via the unrestricted __syscall k_object_alloc and is gated on CONFIG_USERSPACE, CONFIG_DYNAMIC_OBJECTS, and CONFIG_SMP. The flaw was introduced when the per-thread permission index was added in 2018 and is present in every release up to and including v4.4.0. Fixed by holding lists_lock across the bitmap RMW and the permissions clear (and inlining the obj_list traversal that previously took the lock itself).

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:L

Impact Score

5.5

Exploitability

REFERENCES

CVE-2026-66013

SUMMARY

OpenRemote before 1.26.2 contains an authentication bypass vulnerability in the console registration API that allows unauthenticated attackers to update existing console assets by supplying a known asset identifier. Attackers can overwrite push notification tokens and console metadata without authentication or ownership validation, redirecting notifications or denying delivery to legitimate consoles.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-66012

SUMMARY

SiYuan before v3.7.2 contains a missing authorization vulnerability in the POST /mcp kernel endpoint, which is gated only by a general auth check (model.CheckAuth) with no admin-role or read-only enforcement. This exposes 31 MCP tools, including a file tool with list/read/write/delete/rename/copy actions across the entire workspace. When the Publish server is enabled in anonymous mode (Conf.Publish.Enable=true and Conf.Publish.Auth.Enable=false), the Publish reverse proxy attaches an anonymous RoleReader JWT to proxied requests, allowing a remote unauthenticated attacker to reach /mcp. The attacker can read conf/conf.json to extract accessAuthCode, api.token, and cookieKey in plaintext, write arbitrary files in the workspace, and plant a plugin into data/plugins/ that executes with nodeIntegration:true and no contextIsolation on the next desktop launch, leading to administrator takeover.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 10)

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 10.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

CVE-2026-66011

SUMMARY

ImageMagick before 7.1.2-27 contains a memory leak vulnerability in the magick command-line interface when invalid options are provided. Attackers can trigger memory exhaustion by repeatedly supplying malformed command-line arguments to consume system resources.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:L

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.8

REFERENCES

CVE-2026-64529

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: crypto: qat - remove unused character device and IOCTLs The QAT driver exposes a character device (qat_adf_ctl) with IOCTLs for device configuration, start, stop, status query and enumeration. These IOCTLs are not part of any public uAPI header and have no known in-tree or out-of-tree users. Device lifecycle is already managed via sysfs. The ioctl interface also increases the attack surface and is the subject of a number of bug reports. Remove the character device, the IOCTL definitions, and the related data structures (adf_dev_status_info, adf_user_cfg_key_val, adf_user_cfg_section, adf_user_cfg_ctl_data). Drop the now-unused adf_cfg_user.h header and strip adf_ctl_drv.c down to the minimal module_init/module_exit hooks for workqueue, AER, and crypto/compression algorithm registration. Clean up leftover dead code that was only reachable from the removed IOCTL paths: adf_cfg_del_all(), adf_devmgr_verify_id(), adf_devmgr_get_num_dev(), adf_devmgr_get_dev_by_id(), adf_get_vf_real_id() and the unused ADF_CFG macros. Additionally, drop the entry associated to QAT IOCTLs in ioctl-number.rst.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…